Enanta Pharmaceuticals, Inc.
ENTAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Enanta Pharmaceuticals, Inc. (ENTA) is listed under Biotechnology. At a $339.0M market cap, Enanta Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Market Cap
$339.0M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-4.90
EPS (TTM)
$-2.43
EPS (Fwd)
$-2.37
ROE
-70.1%
ROA
-12.3%
Cash
$189.5M
Total Debt
$182.0M
Free CF
-$22.7M
52W Change
10.8%
Annual Financials
Cash vs Debt
Where ENTA stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, ENTA finished 13.11% below its 150-day moving average ($13.20) and 13.95% below its 200-day moving average ($13.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENTA overbought or oversold?
At the October 16, 2026 close, ENTA's RSI(14) was 45.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Enanta Pharmaceuticals, Inc. holds $189.5M in cash against $182.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$22.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -70.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $86.2M (2022) to $65.3M (2025), a 24% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ENTA.